Evaluation of host-based molecular markers for the early detection of human sepsis
•Assay is based on host-response, NOT on pathogen detection•Assay detects sepsis 2–3 days before the first clinical signs•Assay is robust (DNA-based)•Assay uses serum or plasma without further isolation/purification steps We have identified 24 molecular markers, based on circulating nucleic acids (C...
Saved in:
Published in | Journal of biotechnology Vol. 310; pp. 80 - 88 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
20.02.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •Assay is based on host-response, NOT on pathogen detection•Assay detects sepsis 2–3 days before the first clinical signs•Assay is robust (DNA-based)•Assay uses serum or plasma without further isolation/purification steps
We have identified 24 molecular markers, based on circulating nucleic acids (CNA) originating from the human genome, which in combination can be used in a quantitative real-time PCR (qPCR) assay to identify the presence of human sepsis, starting two to three days before the first clinical signs develop and including patients who meet the SEPSIS-3 criteria. The accuracy was more than 87 % inside of the same patient cohort for which the markers were developed and up to 81 % in blind studies of patient cohorts which were not included in the marker development. As our markers are host-based, they can be used to capture bacterial as well as fungal sepsis, unlike the current PCR-based tests, which require species-specific primer sets for each organism causing human sepsis. Our assay directly uses an aliquot of cell-free blood as the substrate for the PCR reaction, thus allowing to obtain the diagnostic results in three to four hours after the collection of the blood samples. |
---|---|
ISSN: | 0168-1656 1873-4863 |
DOI: | 10.1016/j.jbiotec.2020.01.013 |